Data from Von-Hippel-Lindau Clinical Trial Shows Promise for HIF-2a Inhibitor

Eric Jonasch, MD, Professor, Department of Genitourinary medical Oncology at MD Anderson Center provides a preview of his oral presentation planned for 2020 ASCO Virtual Scientific Program in June that summarized the data from a phase II clinical trial assessing the safety and efficacy of MK-6482 in treating patients with Von Hippel-Lindau disease-associated renal cell carcinoma.

The results are published in abstract form in association with ASCO 2020.

Von Hippel-Lindau disease is a genetic characterized by the formation of tumors and cysts in many different parts of the body. The condition can result in a variety of noncancerous or cancerous tumors due to mutations in the VHL gene. People with von Hippel-Lindau disease are also at increased risk for developing other cancers, including renal cell carcinoma.